Sutro Biopharma, Inc. (STRO)
21.39
+0.90
(+4.39%)
USD |
NASDAQ |
Aug 25, 16:00
21.39
0.00 (0.00%)
After-Hours: 19:59
Sutro Biopharma Total Liabilities (Quarterly) : 297.78M for June 30, 2026
Total Liabilities (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Total Liabilities (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 297.78M |
| March 31, 2026 | 308.88M |
| December 31, 2025 | 306.28M |
| September 30, 2025 | 296.93M |
| June 30, 2025 | 294.47M |
| March 31, 2025 | 347.24M |
| December 31, 2024 | 342.61M |
| September 30, 2024 | 340.61M |
| June 30, 2024 | 336.87M |
| March 31, 2024 | 305.38M |
| December 31, 2023 | 321.09M |
| September 30, 2023 | 319.39M |
| June 30, 2023 | 310.18M |
| March 31, 2023 | 172.60M |
| December 31, 2022 | 189.90M |
| September 30, 2022 | 170.97M |
| June 30, 2022 | 176.56M |
| March 31, 2022 | 83.30M |
| Date | Value |
|---|---|
| December 31, 2021 | 88.84M |
| September 30, 2021 | 87.89M |
| June 30, 2021 | 52.29M |
| March 31, 2021 | 51.19M |
| December 31, 2020 | 62.06M |
| September 30, 2020 | 63.12M |
| June 30, 2020 | 70.78M |
| March 31, 2020 | 71.79M |
| December 31, 2019 | 58.58M |
| September 30, 2019 | 61.77M |
| June 30, 2019 | 69.26M |
| March 31, 2019 | 71.74M |
| December 31, 2018 | 91.60M |
| September 30, 2018 | 99.21M |
| June 30, 2018 | |
| March 31, 2018 | |
| December 31, 2017 | 47.26M |
Total Liabilities Definition
Liabilities are a main portion of the balance sheet of a company that measure outstanding payables/obligations. A few examples of liabilties of a company include accounts payable, current debt, and capital lease obligations. From an accounting perspective, the balance sheet equation is Liabilties = Assets - Shareholder's Equity.
Total Liabilities (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Total Liabilities (Quarterly) Benchmarks
| Praxis Precision Medicines, Inc. | 49.06M |
| Upstream Bio, Inc. | 10.21M |
| ACADIA Pharmaceuticals, Inc. | 436.29M |
| Alnylam Pharmaceuticals, Inc. | 4.205B |
| Anika Therapeutics, Inc. | 46.19M |
Total Liabilities (Quarterly) Related Metrics
| Total Assets (Quarterly) | 194.46M |
| Shareholders Equity (Quarterly) | -103.32M |
| Debt to Equity Ratio | -2.418 |
| Current Ratio | 3.320 |
| Net Debt Paydown Yield | -1.39% |